Cantor Fitzgerald Maintains a 'Hold' on Hologic (HOLX); Acquisition Overshadows Challenging Quarter
Tweet Send to a FriendGet Alerts HOLX Hot Sheet
Price: $20.39 -0.34%
Rating Summary:
16 Buy, 6 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Rating Summary:
16 Buy, 6 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Trade HOLX Now!
Cantor Fitzgerald maintains a 'Hold' on Hologic (NASDAQ: HOLX) price target raised from $18 to $20.
Analyst, Jeremy Feffer, said, "The Gen-Probe (Nasdaq: GPRO) acquisition is a bold move and should pay dividends in the long term, but near-term growth concerns (Breast Health, GYN Surgical) persist, while integration will take some time. Our price target goes to $20, but we would still await a better entry point."
"Our 2012 revenue and EPS estimates come down slightly (from $1.37 to $1.36) on the Adiana discontinuation, and our 2013 model will not incorporate Gen-Probe until the acquisition closes. We like the deal long-term, but we remain concerned about the growth constraints near-term, particularly in the Breast Health and GYN Surgical segments."
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $19.12 yesterday, with a 52 week range of $13.90-$23.24.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jeremy Feffer, said, "The Gen-Probe (Nasdaq: GPRO) acquisition is a bold move and should pay dividends in the long term, but near-term growth concerns (Breast Health, GYN Surgical) persist, while integration will take some time. Our price target goes to $20, but we would still await a better entry point."
"Our 2012 revenue and EPS estimates come down slightly (from $1.37 to $1.36) on the Adiana discontinuation, and our 2013 model will not incorporate Gen-Probe until the acquisition closes. We like the deal long-term, but we remain concerned about the growth constraints near-term, particularly in the Breast Health and GYN Surgical segments."
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $19.12 yesterday, with a 52 week range of $13.90-$23.24.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jefferies Lifts Numbers on Diana Shipping (DSX) Post Q1
- Notable HP (HPQ) Bear Speaks, Says 'Recovery Unsustainable'
- Topeka Capital Upgrades Pacific Sunwear of California (PSUN) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change, Mergers and AcquisitionsRelated Entities
Cantor Fitzgerald, Dividend
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
